<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Infection</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6DC31837-4293-4838-972E-B70F4401FDE0"><gtr:id>6DC31837-4293-4838-972E-B70F4401FDE0</gtr:id><gtr:firstName>Heiner</gtr:firstName><gtr:surname>Grosskurth</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A7E4A556-6F0D-4CCF-97A0-3FA60E38CE8C"><gtr:id>A7E4A556-6F0D-4CCF-97A0-3FA60E38CE8C</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:surname>Gilks</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FE9EA012-6C07-4F91-B86B-E3E69CC5A70F"><gtr:id>FE9EA012-6C07-4F91-B86B-E3E69CC5A70F</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Ndimbirwe</gtr:otherNames><gtr:surname>Mugyenyi</gtr:surname><gtr:orcidId>0000-0002-9183-9973</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/108B404C-64E2-49D7-A53C-7E341ED636BD"><gtr:id>108B404C-64E2-49D7-A53C-7E341ED636BD</gtr:id><gtr:firstName>Cissy</gtr:firstName><gtr:surname>Kityo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/96D43A36-8970-46E6-8DF4-0FA40E944EFC"><gtr:id>96D43A36-8970-46E6-8DF4-0FA40E944EFC</gtr:id><gtr:firstName>Paula</gtr:firstName><gtr:surname>Munderi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/034DF7C9-8F6E-4D04-BD15-58E9F56517F1"><gtr:id>034DF7C9-8F6E-4D04-BD15-58E9F56517F1</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Yirrell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/28492226-1F58-4BA7-8B6F-FCC94B86ECD9"><gtr:id>28492226-1F58-4BA7-8B6F-FCC94B86ECD9</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Chirara</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EC09F527-4916-4235-9F6C-846D1C65CF1C"><gtr:id>EC09F527-4916-4235-9F6C-846D1C65CF1C</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Gita</gtr:otherNames><gtr:surname>Hakim</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4CFEE661-9281-4E12-B253-109123EF97A4"><gtr:id>4CFEE661-9281-4E12-B253-109123EF97A4</gtr:id><gtr:firstName>Ann</gtr:firstName><gtr:otherNames>Sarah</gtr:otherNames><gtr:surname>Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FFDC9303-106E-40FA-A0EB-273BB9B5515D"><gtr:id>FFDC9303-106E-40FA-A0EB-273BB9B5515D</gtr:id><gtr:firstName>Val</gtr:firstName><gtr:surname>Robertson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DE3BB758-BDB7-4F11-9F17-A0CEBB70F1A3"><gtr:id>DE3BB758-BDB7-4F11-9F17-A0CEBB70F1A3</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Reid</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/58B69503-B9E3-43E3-AEB2-82D521E4C95E"><gtr:id>58B69503-B9E3-43E3-AEB2-82D521E4C95E</gtr:id><gtr:firstName>Diana</gtr:firstName><gtr:surname>Gibb</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F4C48495-1923-4707-89F9-8E633268BD2A"><gtr:id>F4C48495-1923-4707-89F9-8E633268BD2A</gtr:id><gtr:firstName>Deenan</gtr:firstName><gtr:surname>Pillay</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5"><gtr:id>B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5</gtr:id><gtr:firstName>Pontiano</gtr:firstName><gtr:surname>Kaleebu</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/168CFD16-EA26-4A8A-B3E6-5E11BD817F3E"><gtr:id>168CFD16-EA26-4A8A-B3E6-5E11BD817F3E</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Tyre</gtr:otherNames><gtr:surname>Dunn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600044"><gtr:id>929F6FE0-3B8C-4185-85D0-9593C774C11E</gtr:id><gtr:title>The emergence and impact of HIV resistance-associated mutations under the public health approach to ART</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600044</gtr:grantReference><gtr:abstractText>AIDS is one of the major killers worldwide. The epidemic is growing by the day, and some of the poorest countries are being decimated by deaths amongst young adults and children. Meanwhile, the use of antiretroviral therapy in the resource-rich areas of the world has had enormous benefits to those living with the infection. HIV is no longer a death sentence, and rather has become a chronic disease, requiring daily medication to maintain wellbeing. Until recently, the costs of such treatment have precluded it being available to those areas of the resource-poor world which host the huge bulk of the epidemic. However, a roll out of therapy, funded from a number of initiatives has now started to make such therapy available. The WHO has developed a simple template for the implementation of such treatment. However, the use of sophisticated laboratory monitoring of treatment, as routinely occurs in the West, is not realistic. Such monitoring is typically used in the West to measure the amount of virus in the blood in those receiving treatment. Since effective treatment reduces the levels of virus to very low levels, an increase in such levels suggests that the treatment is working less well. In such situations, the virus is tested to detect resistance to one or more of the drugs being taken, and this can guide the appropriate 2nd line of therapy to start. In this way, high level resistance is minimised. By contrast, in the resource-poor world, these sophisticated and expensive laboratory tests will not be available, and therefore there is a distinct risk that people starting on treatment will end up with highly drug resistant virus, which may not respond well to further treatment. 

We aim to investigate the extent of this problem, within a large group of patients treated for HIV in Uganda and Zimbabwe. Our research will identify simple and cheap methods to monitor those receiving treatment in this environment, in order to minimise the risk of such resistance, such that improvements in survival due to antiretroviral therapy can be maintained over a long period of time. Our results will directly inform WHO policy regarding the manner in which treatment is made available to the resource-poor world.</gtr:abstractText><gtr:technicalSummary>Rollout of antiretroviral therapy (ART) in resource-limited countries, where HIV prevalence is highest, has been identified as a priority by the World Health Organisation (WHO), bilateral donors, multilateral agencies and the countries themselves. The number of people receiving therapy has more than doubled in the last 2 years, most notably in sub-Saharan Africa where approximately 500,000 people started ART in 2005. In the resource-rich world, ART use is accompanied by intensive virological monitoring , to identify early stages of viral rebound at which time treatment is switched. This reduces the risk of extensive drug resistance, as well as prolonging the efficacy of ART, through subsequent treatment switches. By contrast, in the resource poor world, there is neither the infrastructure, nor resource to undertake such testing, and the public health approach to ART rollout is based on the use of standard 1st and 2nd line drug regimens, with treatment switch determined by clinical disease progression. This carries with it risks for development of high level resistance. There is thus need for an evidence-based approach to public-health based rollout of ART in resource-limited environments in order to maximise the potential benefit of ART on long-term survival (first and second line therapy), given that resistance to antiretroviral drugs will inevitably develop. 

The quantification of both the risk and determinants of resistance and delineation of the relationship between disease progression, virological and immunological changes and the development of resistance in resource-limited settings in Africa is the focus of this application. Specifically we aim to fully explore disease progression (clinical, immunological and virological) in patients with ongoing viraemia during first-line treatment with three different combivir-based regimens, within the DART Trial, in order to: a) determine the evolution of resistance in the absence of virological monitoring, and therefore identify the implications for NRTI use within a boosted PI-containing second-line ART b) identify simple markers of extensive and clinically relevant resistance during 1st line therapy which can be implemented in a resource-limited environment to guide treatment switch to second-line therapy c) study virological determinants of disease progression during 1st line therapy in the absence of virological monitoring</gtr:technicalSummary><gtr:fund><gtr:end>2011-04-10</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-11</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>949229</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC/UVRI Uganda Research Unit on AIDS</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>CHAIN- an FP7 funded Integrated Project (RTD REG/F.6(2009)D/536661}</gtr:description><gtr:id>47551FF9-F435-4655-9FD5-9F87F04F4D66</gtr:id><gtr:impact>Disciplines- virology, epidemiology
Established (2009) working programme to identify virological consequences of ARV rollout with limited virological monitoring
Work in progress.</gtr:impact><gtr:outcomeId>miiikk7vHjJ-1</gtr:outcomeId><gtr:partnerContribution>Exchange of students/post docs</gtr:partnerContribution><gtr:piContribution>MRC AIDS programme in Uganda becoming a component on EU wide HIV virology network.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Africa AIDS Patient groups</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D9AA606C-ED90-47EF-A9A0-DD950C6A4AEB</gtr:id><gtr:impact>Research part of the DART trial of HIv treatment in Africa. Multiple interactions with African media, patient participation groups.

Support change in WHO policy</gtr:impact><gtr:outcomeId>DF63F94197F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Community Engagement Unit, Africa Centre for Population Health</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D5F4F26F-E0B0-4FCA-8B81-A28E26DD3B1B</gtr:id><gtr:impact>Roadshows within the research population of Africa Centre for Population Health in rural KwaZulu-Natal, South Africa. Radio shows in local language to report on research findings.</gtr:impact><gtr:outcomeId>57dff4677bc117.89759406</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Fellowship</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>5E4B8F8C-970A-4C77-9BAA-F397BB88785F</gtr:id><gtr:outcomeId>FFB710F181D0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centre Grant</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A415EC03-4A57-46A3-8C94-534B062E4BC6</gtr:id><gtr:outcomeId>C63875138190</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Strategic Award</gtr:description><gtr:end>2021-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>7ED2D48B-0020-450B-A9CA-5A579F02346E</gtr:id><gtr:outcomeId>57dff3988ec926.12760520</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>341601</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CHAIN Collaborative HIV and Anti-HIV Drug Resistance Network (10m euros across 24 participants)</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>838C4E31-090A-485E-8805-0C9A0695DCB0</gtr:id><gtr:outcomeId>CFAAF5CA8A20</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Infrastructure</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>034E7524-6308-4DAD-88AD-69D899636565</gtr:id><gtr:outcomeId>943226BF6450</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5909061</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>HIV Phylogenetics Consortium</gtr:description><gtr:end>2016-11-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>5191FE46-8A08-409B-BFBF-CD9E226EAC4E</gtr:id><gtr:outcomeId>Ku1mjgRR66p</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO HIV Drug Resistance Committee</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D1441708-6CF8-4025-AACD-355C9651EBB4</gtr:id><gtr:outcomeId>0717B3A55B3</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Triple transfection, single cycle HIV drug susceptibility assay. Novelty includes incorporation of full length gag, protease, and full length reverse transcriptase genes</gtr:description><gtr:id>974454D8-D427-41A0-A327-26FD2267E224</gtr:id><gtr:impact>Identification of new determinants of HIV drug resistance</gtr:impact><gtr:outcomeId>tEtj56DuRig</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Drug resistance phneotype methodology</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>34D857B1-4A85-4F46-8DC9-F5DBA0A53F06</gtr:id><gtr:title>Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a90b45f679d889fd75b95b5af0f57380"><gtr:id>a90b45f679d889fd75b95b5af0f57380</gtr:id><gtr:otherNames>Wittkop L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5488761e8826e1.29150157</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>332C0E8E-D239-4045-9CF9-8AEA4CCBC18C</gtr:id><gtr:title>Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3351d89d5f121bef6fc5cb4126499a9b"><gtr:id>3351d89d5f121bef6fc5cb4126499a9b</gtr:id><gtr:otherNames>Goodall RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>58c6a803e6eb52.30301979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98ADF8D1-21A9-4E00-9B24-259E49022A2E</gtr:id><gtr:title>The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9859179eab8d2f5d7df659dae68e5864"><gtr:id>9859179eab8d2f5d7df659dae68e5864</gtr:id><gtr:otherNames>Dolling DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>58c6a803afecb0.35457036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCD9BED4-B89E-4D85-88E1-2E9D4A3448EC</gtr:id><gtr:title>Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a115fb22ae8b5eb1d761afe50087d24"><gtr:id>9a115fb22ae8b5eb1d761afe50087d24</gtr:id><gtr:otherNames>McCormick AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>DCZU89U6W8T</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECBCE120-AD38-4458-ADA1-9B45C37E27B3</gtr:id><gtr:title>From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a812e4f1abe545f9b5ed7c881ce39f76"><gtr:id>a812e4f1abe545f9b5ed7c881ce39f76</gtr:id><gtr:otherNames>Namakoola I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>58c6a8042f7754.06585091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>845B380F-D133-460A-AC40-C0480689403C</gtr:id><gtr:title>Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1468a3c79a930345b1162a38bc32d1aa"><gtr:id>1468a3c79a930345b1162a38bc32d1aa</gtr:id><gtr:otherNames>Gupta RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>BmpdrR1SEdD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B843D2D7-EB9E-455F-AC9B-D8521683A0A5</gtr:id><gtr:title>Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a8bde31d95ec586098b2322368ff463"><gtr:id>5a8bde31d95ec586098b2322368ff463</gtr:id><gtr:otherNames>Ndembi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>kMYxrgju4Fv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A60C6365-9452-4BDA-8C12-669063A7D1A9</gtr:id><gtr:title>HIV type 1 in a rural coastal town in Kenya shows multiple introductions with many subtypes and much recombination.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d0e4078101e2913852def3cc79eff29"><gtr:id>0d0e4078101e2913852def3cc79eff29</gtr:id><gtr:otherNames>Hu? S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>5488761fbf7627.51265245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B460FB2-8247-4C58-8FC2-D7CDF4FC8E61</gtr:id><gtr:title>Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/051cf62d6d905f0304eb0c4d1af8ba2e"><gtr:id>051cf62d6d905f0304eb0c4d1af8ba2e</gtr:id><gtr:otherNames>Lyagoba F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>iCFzpqLLrBJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0595E14A-0AE5-4546-B2F3-661C90717B13</gtr:id><gtr:title>Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7da11026bd77b80de9adabc4b8b7c17f"><gtr:id>7da11026bd77b80de9adabc4b8b7c17f</gtr:id><gtr:otherNames>Sutherland KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>57dff1ff7cd717.20693613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C243CC4-F8DD-4CFA-AB38-DDD338E70C3A</gtr:id><gtr:title>Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09843440e2f526123c605f0f6c9bc916"><gtr:id>09843440e2f526123c605f0f6c9bc916</gtr:id><gtr:otherNames>Gregson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>58c6a80463a338.99959797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E51A2056-2C0A-453B-B1CE-B6D58CFB03B3</gtr:id><gtr:title>Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fff9ad9ad870a670fe88aee2fe4bc105"><gtr:id>fff9ad9ad870a670fe88aee2fe4bc105</gtr:id><gtr:otherNames>Gupta R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>sTaXCzozPLv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC60AE3C-64DE-4D6A-99DB-045E6A5D5E12</gtr:id><gtr:title>Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c46f2d9ffe46edb4c77cc56e89bb86f5"><gtr:id>c46f2d9ffe46edb4c77cc56e89bb86f5</gtr:id><gtr:otherNames>TenoRes Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>58c6a804900760.65827367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3D169A2-20BA-4130-B52C-F3ED979DF510</gtr:id><gtr:title>Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f76496409ebd723eb37f62919a49eeb"><gtr:id>4f76496409ebd723eb37f62919a49eeb</gtr:id><gtr:otherNames>Gilks CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>YFt2PMrfVtt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F71E265-F442-4E84-9BA5-9803C928154F</gtr:id><gtr:title>The Impact of HIV Drug Resistance on the Selection of First- and Second-Line ART in Resource-Limited Settings.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6937d74631c774dc24952e76c2009a3a"><gtr:id>6937d74631c774dc24952e76c2009a3a</gtr:id><gtr:otherNames>Bertagnolio S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>5488767d61f3c0.02541519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B66DAFE-EA1D-4EBF-8689-4E023523D284</gtr:id><gtr:title>Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c364bb47d84d53cfc830c1a911aa5fdf"><gtr:id>c364bb47d84d53cfc830c1a911aa5fdf</gtr:id><gtr:otherNames>Mbisa JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>57dff298306863.03339484</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600044</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>